Results 151 to 160 of about 21,507 (209)
Some of the next articles are maybe not open access.
Arthritis & Rheumatism, 1976
AbstractThe clinical and laboratory experience with the lupus anticoagulant was reviewed in 37 patients. The anticoagulant is thought to act by blocking the activation of prothrombin by the prothrombin activator complex of factors Xa, V, and phospholipid.
M, Boxer, L, Ellman, A, Carvalho
openaire +2 more sources
AbstractThe clinical and laboratory experience with the lupus anticoagulant was reviewed in 37 patients. The anticoagulant is thought to act by blocking the activation of prothrombin by the prothrombin activator complex of factors Xa, V, and phospholipid.
M, Boxer, L, Ellman, A, Carvalho
openaire +2 more sources
Lupus anticoagulant in pregnancy
BJOG: An International Journal of Obstetrics & Gynaecology, 1984summaryIn a group of 10 women with circulating lupus anticoagulant 25 intrauterine deaths were previously documented in the nine multigravidae. The presence of lupus anticoagulant activity was confirmed by showing prolongation of the activated partial thromboplastin time and kaolin clotting time with failure of correction of the prolongation on ...
W F, Lubbe +3 more
openaire +4 more sources
The challenges of lupus anticoagulants
Expert Review of Hematology, 2016The term "lupus anticoagulant" (LA) refers to a heterogeneous group of immunoglobulins behaving as acquired in vitro inhibitors of coagulation. These antibodies, namely anti-β2GPI and anti-prothrombin antibodies, induce the in vitro elongation of clotting time interfering with phospholipid-dependent coagulation cofactors. Positive LA is associated with
C.B. Chighizola +5 more
openaire +2 more sources
Lupus anticoagulant in myelofibrosis
The American Journal of the Medical Sciences, 1976A patient with myelofibrosis who also demonstrates a lupus anticoagulant is reported. The presence of a circulating anticoagulant adds to the list of potential hemorrhagic diatheses in myelofibrosis and also demonstrates myelofibrosis to involve a system that may be separate from the myeloid elements of the bone marrow.
B, Bernhardt, M, Valletta
openaire +2 more sources
Lupus Anticoagulant and Stroke
Archives of Neurology, 1987To the Editor. —Tabachnik-Schor and Lipton's 1 recent report of a case of nonvasculitic cerebral infarction associated with a lupuslike anticoagulant (LA) suggests that their case is the first without "other causes of vasculopathy." Several features of their patient's case do not appear to support their conclusion. Their patient's skin biopsy specimen
S R, Levine, K M, Welch
openaire +2 more sources
Lupus anticoagulant and pregnancy
American Journal of Obstetrics and Gynecology, 1985A subset of women with a high rate of fetal wastage is identifiable among those with serologic but not necessarily clinical evidence of connective tissue disease. The presence of lupus anticoagulant in the plasma of a pregnant woman serves as a marker for a high rate of fetal wastage and risk of thrombosis. Lupus anticoagulant is best identified by the
W F, Lubbe, G C, Liggins
openaire +2 more sources
Neurology and the Lupus Anticoagulant
European Neurology, 1985The lupus anticoagulant, an immunoglobulin of the IgG or IgM class, is one of a group of antiphospholipid antibodies. Although an anticoagulant in vitro, its action in vivo is that of a procoagulant. This procoagulant activity may involve many organ systems including the nervous system.
H, Englert, G, Derue, G R, Hughes
openaire +2 more sources
Testing for Lupus Anticoagulants
Seminars in Thrombosis and Hemostasis, 2022AbstractLupus anticoagulant (LA) is one of the three criteria antiphospholipid antibodies (aPLs) employed in classification, and by default diagnosis, of antiphospholipid syndrome (APS). Detection of LA is not via calibrated assays but is based on functional behavior of the antibodies in a medley of coagulation assays.
openaire +2 more sources
British Journal of Haematology, 1987
SummaryThree families having more than one affected member with SLE or lupus‐like disease were investigated by global coagulation tests as well as methods based on dilute thromboplastin, Russell's viper venom and thermal stability/absorption, and by RIA for anticardiolipin (CL) antibodies. Of the 19 persons, 11 had SLE or lupus‐like disease.
I J, Mackie, C B, Colaco, S J, Machin
openaire +2 more sources
SummaryThree families having more than one affected member with SLE or lupus‐like disease were investigated by global coagulation tests as well as methods based on dilute thromboplastin, Russell's viper venom and thermal stability/absorption, and by RIA for anticardiolipin (CL) antibodies. Of the 19 persons, 11 had SLE or lupus‐like disease.
I J, Mackie, C B, Colaco, S J, Machin
openaire +2 more sources
The Lupus Anticoagulant Paradox
Seminars in Thrombosis and Hemostasis, 2017AbstractLupus anticoagulant (LA) represents the most enigmatic antibody population in patients with antiphospholipid syndrome and represents a paradox that is still unsolved. This class of antiphospholipid antibody causes a phospholipid-dependent prolongation of the clotting time but is associated with an increased risk of thrombosis and pregnancy ...
Jessica E, Molhoek +2 more
openaire +2 more sources